Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

>2 years >20 visits Efficacy phase (II)Confirmation phase (III)No Placebo Cost Reimbursement Standard Medicines Oral InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Bendamustin Actavis

Bendamustin Actavis is a chemotherapy medicine used to treat certain blood cancers, such as lymphoma and chronic lymphocytic leukemia.

Bendamustin Hikma

Bendamustin Hikma is a chemotherapy medicine used to treat certain blood and lymph cancers, such as lymphoma and chronic lymphocytic leukemia.

Mabthera

Mabthera is a medicine used to treat certain blood cancers and some autoimmune diseases by targeting problematic immune cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bendamustine Hydrochloride

Bendamustine hydrochloride is a chemotherapy substance used to treat certain blood cancers by killing cancer cells.

Rituximab

Rituximab is a substance that targets and reduces B cells, a type of white blood cell, to treat some blood cancers and autoimmune conditions.

Zanubrutinib

Zanubrutinib is a substance that treats certain B‑cell blood cancers by blocking a protein that helps cancerous B cells grow.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Benda Nc

Bendamedac

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Ordensklinikum Linz GmbH

I. Interne Abteilung

Linz, Austria

Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Universitätsklinik für Innere Medizin III

Salzburg, Austria

Medical University Of Vienna

Universitätsklinik für Innere Medizin I

Vienna, Austria

Sponsor: BeOne Medicines AG

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.